Results of the PROPINE randomized controlled study suggest tapering of prednisone treatment for relapses of steroid sensitive nephrotic syndrome is not necessary in children.

[1]  M. Davidovits,et al.  Lower prednisone dosing for steroid-sensitive nephrotic syndrome relapse: a prospective randomized pilot study , 2019, European Journal of Pediatrics.

[2]  J. Deeks,et al.  Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation , 2019, BMJ.

[3]  J. Piette,et al.  Text Messaging for Disease Monitoring in Childhood Nephrotic Syndrome , 2019, Kidney International Reports.

[4]  A. Connolly,et al.  Management of Adrenal Insufficiency Risk After Long-term Systemic Glucocorticoid Therapy in Duchenne Muscular Dystrophy: Clinical Practice Recommendations , 2019, Journal of neuromuscular diseases.

[5]  F. Emma,et al.  Equations to estimate prednisone dose using body weight , 2018, Pediatric Nephrology.

[6]  R. Parekh,et al.  Idiopathic nephrotic syndrome in children , 2018, The Lancet.

[7]  C. Mammen,et al.  Induction prednisone dosing for childhood nephrotic syndrome: how low should we go? , 2018, Pediatric Nephrology.

[8]  N. Roeleveld,et al.  REducing STEroids in Relapsing Nephrotic syndrome: the RESTERN study— protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study , 2017, BMJ Open.

[9]  L. Peruzzi,et al.  The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part I - Diagnosis and treatment of the first episode and the first relapse , 2017, Italian Journal of Pediatrics.

[10]  F. Emma,et al.  Minimal Change Disease. , 2017, Clinical journal of the American Society of Nephrology : CJASN.

[11]  E. Ota,et al.  A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment , 2014, Kidney international.

[12]  A. Sinha,et al.  Extending initial prednisolone treatment in a randomized control trial from 3 to 6 months did not significantly influence the course of illness in children with steroid-sensitive nephrotic syndrome. , 2015, Kidney international.

[13]  J. Rotteveel,et al.  Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia. , 2015, The Cochrane database of systematic reviews.

[14]  J. Craig,et al.  Non‐Corticosteroid Immunosuppressive Medications for Steroid‐Sensitive Nephrotic Syndrome in Children , 2013, The Cochrane database of systematic reviews.

[15]  W. Hop,et al.  Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. , 2013, Journal of the American Society of Nephrology : JASN.

[16]  D. Gipson,et al.  Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO , 2013, Pediatric Nephrology.

[17]  F. Emma,et al.  Time for initial response to steroids is a major prognostic factor in idiopathic nephrotic syndrome. , 2010, The Journal of pediatrics.

[18]  S. Rittig,et al.  Early age at debut is a predictor of steroid-dependent and frequent relapsing nephrotic syndrome , 2010, Pediatric Nephrology.

[19]  F. Emma,et al.  Risk factors for cyclosporin A nephrotoxicity in children with steroid-dependant nephrotic syndrome. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[20]  P. Hindmarsh,et al.  Adrenocortical suppression increases the risk of relapse in nephrotic syndrome , 2007, Archives of Disease in Childhood.

[21]  J. Craig,et al.  Corticosteroid therapy for nephrotic syndrome in children. , 2020, The Cochrane database of systematic reviews.

[22]  J. Perheentupa,et al.  ASSOCIATION OF POSTMEDICATION HYPOCORTISOLISM WITH EARLY FIRST RELAPSE OF IDIOPATHIC NEPHROTIC SYNDROME , 1977, The Lancet.